九典制药拟收购诺纳医药10%股权 巩固控股地位

Core Viewpoint - The company plans to use its own funds of 46.5845 million yuan to acquire a 10% stake in Nona Pharmaceutical held by Shangshan Hongren, increasing its ownership in Nona Pharmaceutical from 60% to 70% [1] Group 1: Company Strategy - The transaction aims to consolidate the company's controlling position in Nona Pharmaceutical [1] - This move is part of the company's strategy to deepen its layout in the biopharmaceutical sector [1]